Today: 21 May 2026
Lumentum Stock Nears $960 After JPMorgan, Mizuho Raise Targets on Nvidia AI Optics Demand
9 April 2026
2 mins read

Lumentum Stock Nears $960 After JPMorgan, Mizuho Raise Targets on Nvidia AI Optics Demand

New York, April 9, 2026, 12:15 EDT

JPMorgan bumped its price target on Lumentum to $950 from $565, pushing the stock higher again Thursday. That move came right after Mizuho’s own hike to $930 from $750. Lumentum reached $959.57 in intraday trading and hovered around $899.39, up roughly 0.4% by late morning in New York. Shares already surged 9.8% Wednesday.

Back-to-back calls are drawing attention. Lumentum supplies lasers and optical gear that shuttle data between AI chips—a segment Nvidia is now putting money behind, locking in purchase deals. CPO, which stands for co-packaged optics, brings optics right up close to the chip package to cut electrical loss. Optical switching, on the other hand, routes traffic inside sprawling AI clusters with lower power requirements.

Last month, Nvidia said it would pour $2 billion into Lumentum, also locking in multibillion-dollar orders—a move that helps Lumentum boost its manufacturing plans. Not long after, Lumentum announced plans for a 240,000-square-foot laser facility set for Greensboro, North Carolina. Nvidia’s on board as a customer, with production at the site aiming to pick up speed by mid-2028.

Nvidia’s Jensen Huang calls AI “the largest computing infrastructure buildout in history.” Lumentum chief Michael Hurlston says the new fab will “increase capacity and accelerate innovation.” NVIDIA Investor Relations

Lumentum posted revenue of $665.5 million on February 3, a jump of 65.5% from the prior year, with non-GAAP earnings landing at $1.67 per share. For the third quarter, the company is projecting revenue in the $780 million to $830 million range and expects adjusted earnings between $2.15 and $2.35 per share.

Hurlston described Lumentum as just getting started in optical circuit switches and CPO. The optical-switch backlog, he noted, has topped $400 million. And there’s already another multi-hundred-million-dollar CPO order on the books—this one set for delivery in the first half of 2027.

Wall Street’s getting more bullish on that story. Mizuho pointed to the company’s investor-day pitch as the reason for hiking its target. JPMorgan’s Samik Chatterjee cited better forward visibility, recent customer deals, and increased capacity as the key factors behind his higher call.

Lumentum isn’t alone—AI-networking vendors are scrambling. Nvidia inked a $2 billion agreement with Coherent, mirroring the size of the Lumentum deal, and Marvell scooped up photonics startup Celestial AI last year. Optical interconnects have become the new battleground for chipmakers.

Lumentum plans to hand out approximately 5.7 million shares to holders of about $474.6 million in convertible notes due 2026 and 2029, according to an SEC filing this week. No cash changes hands in the deal; the note balances shrink, while dilution ticks up by around 0.6 million shares.

Here’s the sticking point: adoption hasn’t yet closed the gap with the narrative. Back in March, Reuters flagged that CPO production was still lagging behind Nvidia’s chip volumes. Jacob Bourne, an eMarketer analyst, pointed out that getting the tech “affordable enough to deploy at scale” remains the big challenge. The note swap, for its part, brings dilution into the mix. Reuters

Lumentum plans to release its fiscal third-quarter numbers after markets shut on May 5, the company said April 6.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround
Previous Story

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal
Next Story

Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

Go toTop